


L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

Claims 14-17



G1 C, Si

G2 Cb, Ak

G3 H, Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:46:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 72 TO ITERATE

100.0% PROCESSED 72 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 931 TO 1949

PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:46:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1594 TO ITERATE

100.0% PROCESSED 1594 ITERATIONS

90 ANSWERS

SEARCH TIME: 00.00.01

L3 90 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.78

FILE 'CAPLUS' ENTERED AT 13:46:59 ON 17 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Aug 2006 VOL 145 ISS 8
FILE LAST UPDATED: 16 Aug 2006 (20060816/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4

41 L3

=> d ibib abs hitstr 1-41

L4 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:365240 CAPLUS

DOCUMENT NUMBER: 144:412505

TITLE: Benzimidazole or indole amides as inhibitors of pin1 and their preparation, pharmaceutical compositions, and use for treatment of diseases associated with abnormal cell growth

INVENTOR(S): Do, Quyen-Quyen Thuy; Guo, Chuangxing; Humphries,

Paul

Stuart; Marakovits, Joseph Timothy; Dong, Liming;

Hou,

Kinjun; Johnson, Mary Catherine

Pfizer, Inc., USA

PCT Int. Appl., 396 pp.

CODEN: PIXXD2

Patent

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006040646	A1	20060420	WO 2005-1B3019	20051003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GW, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-619211P P 20041014


OTHER SOURCE(S): MARPAT 144:412505

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. of the formula I and to pharmaceutically acceptable salts and solvates thereof, wherein the variables are defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compds. of formula I and to pharmaceutical compns. for treating such disorders that contain the compds. of formula I. The invention also relates to methods of preparing the compds. of formula I. Compds. of formula I wherein Q, Q1, Q2, and Q3 are independently N, CH2 or CH, where not more than two of the Qs are N; T is CH or N; T1 is O, NH or NMe; X is NH, O, CH=, or NR'; R' is (un)substituted


L4 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 884035-56-7 CAPLUS
CN 4-Thiazolecarboxylic acid, 4-[(5-fluoro-1H-benzimidazol-2-yl)methyl]-4,5-dihydro-2-(2-naphthalenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 884035-58-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 4-[(6-fluoro-1-(phenylsulfonyl)-1H-indol-2-yl)methyl]-4,5-dihydro-2-(2-naphthalenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 884035-60-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[(1E)-2-(2,6-dichlorophenyl)ethenyl]-4-[(6-fluoro-1-(phenylsulfonyl)-1H-indol-2-yl)methyl]-4,5-dihydro-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

alkyl: Y is CO, CH2, or CONH and deriva.; Z is H or (un)substituted alkyl; XY and X can form a heterocyclic ring or X and Y can form a heterocyclic ring; R and V are independently H, halo, alkyl, halogenated alkyl, alkoxy,

OH, NH2, CN; R1 is (un)substituted (hetero)aryl, (un)substituted aryloxy, (un)substituted arylsulfanyl, (un)substituted arylvinyl or (un)substituted

arylalkyl(amino), etc.; R3 is CO2H, tetrazole, CO2CH2R4OCOR4 or CONH2 and deriva.; R4 is H or alkyl; and their pharmaceutically acceptable salts and

solvates are claimed in this invention. Example compd. II was prep'd. by substitution of compd. II with benzoxazole-2-thiol followed by hydrolysis at the ester. Addnl. 1400 example compds. were prep'd. in this invention. All invention compds. were evaluated for their pin1 inhibitory activity. Example compd. II showed 10% inhibition at 1 μM and 73% inhibition at 10 μM concn. Most of the invention compds. showed good inhibitory activity at 10 μM concn.


IT 884035-51-2P 884035-54-5P 884035-56-7P

884035-58-9P 884035-60-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of benzimidazole or

indole amides as inhibitors of pin1 useful for treatment of diseases


associated with abnormal cell growth)
RN 884035-51-2 CAPLUS
CN 4-Thiazolecarboxylic acid,

2-[2-(2,6-dichlorophenyl)ethyl]-4-[(5-fluoro-1H-benzimidazol-2-yl)methyl]-4,5-dihydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 884035-54-5 CAPLUS
CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-[(1-methyl-1H-benzimidazol-2-yl)methyl]-2-(2-naphthalenyl)-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 884035-65-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazole or indole amides as

inhibitors of pin1 useful for treatment of diseases associated with abnormal cell growth)

RN 884035-65-8 CAPLUS
CN 4-Thiazolecarboxylic acid, 4-[(6-fluoro-1-(phenylsulfonyl)-1H-indol-2-yl)methyl]-4,5-dihydro-2-(2-naphthalenyl)-, ethyl ester (9CI) (CA INDEX NAME)




IT 884048-24-2P 884048-27-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazole or indole amides as


inhibitors of pin1 useful for treatment of diseases associated with abnormal cell growth)

RN 884048-24-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[2-(2,6-dichlorophenyl)ethyl]-4-[(6-fluoro-1-(phenylsulfonyl)-1H-indol-2-yl)methyl]-4,5-dihydro-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 884048-27-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-((9H-fluoren-9-ylmethyl)-4-((6-fluoro-1-(phenylsulfonyl)-1H-indol-2-yl)methyl)-4,5-dihydro-, ethyl ester (9CI)
 (CA INDEX NAME)




IT 884048-35-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of benzimidazole or indole amides as inhibitors of pini useful for treatment of diseases associated with abnormal cell growth)
 RN 884048-35-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4-((6-fluoro-1-(phenylsulfonyl)-1H-indol-2-yl)methyl)-4,5-dihydro-2-((methylsulfonyl)oxy)methyl-, ethyl ester (9CI)
 (CA INDEX NAME)



L4 ANSWER 2 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:334369 CAPLUS
 DOCUMENT NUMBER: 145:62862
 TITLE: Synthesis of chiral cyclic oligothiazolines: a novel structural motif for a macrocyclic molecule
 AUTHOR(S): Han, Fu She; Osajima, Hiroyuki; Cheung, Mui; Tokuyama, Hidetoshi; Fukuyama, Tohru
 CORPORATE SOURCE: PRESTO, the Japan Science and Technology Agency (JST),
 SOURCE: 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
 PUBLISHER: Chemical Communications (Cambridge, United Kingdom)
 DOCUMENT TYPE: (2006), (16), 1757-1759
 LANGUAGE: CODEN: CHCOFS; ISSN: 1359-7345
 AB The synthesis of chiral cyclic oligo(4-β-methyl)thiazolines is described; linear oligothiazolines were efficiently prepared by the iterative formation of a thiazoline ring and a two-directional block condensation, and construction of 24- to 36-membered cyclic oligothiazoline systems could be achieved by the head-to-tail cycloligomerization of doubly deprotected linear fragments and subsequent thiazoline formation.
 IT 890534-13-1P 890534-14-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of chiral cyclic oligothiazolines, a novel structural motif for a macrocyclic mol.)
 RN 890534-13-1 CAPLUS
 CN 4-Thiazolecarboxylic acid,
 2-[(1S)-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-mercapto-1-methylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 890534-14-2 CAPLUS
 CN 4-Thiazolecarboxylic acid,
 2-[(1S)-2-[[[(4S)-4,5-dihydro-4-methyl-2-[(4S)-4-methyl-2-oxo-4-thiazolidinyl]-4-thiazolyl]carbonyl]thio]-1-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-methylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 2 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 3 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:308379 CAPLUS

DOCUMENT NUMBER: 144:480803

TITLE:

(S)-4,5-Dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic Acid Polyethers: A Solution to Nephrotoxicity

AUTHOR(S): Bergeron, Raymond J.; Wiegand, Jan; McManis, James S.;

CORPORATE SOURCE: Vinson, John R. T.; Yao, Hua; Bharti, Neelam; Rocca, James R.
Department of Medicinal Chemistry and the Advanced Magnetic Resonance Imaging and Spectroscopy Facility, University of Florida, Gainesville, FL, 32610-0485, USA

SOURCE: Journal of Medicinal Chemistry (2006), 49(9), 2772-2783

CODEN: JMCMAJ; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Previous studies revealed that within a family of ligands the more lipophilic chelators have better iron-clearing efficiency. The larger the log Papp value of the compound, the better the iron-clearing efficiency. What is also clear from the data is that although the relative effects of log Papp changes are essentially the same through different families, there are differences in absolute value between families. However, there also

exists a second, albeit somewhat more disturbing, relationship. In all sets of ligands, the most lipophilic chelator is always the most toxic. The current study focuses on designing ligands that balance the lipophilicity/toxicity problem while iron-clearing efficiency is maintained. Earlier studies with (S)-4,5-dihydro-2-(2-hydroxy-4-methoxyphenyl)-4-methyl-4-thiazolecarboxylic acid [(S)-4'-(CH₃O)-DADFT,

6] indicated that this Me ether was a ligand with excellent iron-clearing efficiency in both rodents and primates; however, it was too toxic. On the basis of this finding, a less lipophilic, more water-soluble ligand

than 6 was assembled, (S)-4,5-dihydro-2-(2-hydroxy-4-(3,6,9-trioxadecyloxy)phenyl)-4-methyl-4-thiazolecarboxylic acid [(S)-4'-(HO)-DADFT-PE, 11], a polyether analog, along with its Et and iso-Pr esters. The parent polyether and its iso-Pr and Et esters were

all shown to be highly efficient iron chelators in both rodents and primates. A comparison of 11 in rodents with the desferriethiocin analog (S)-4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methyl-4-thiazolecarboxylic

acid [(S)-4'-(HO)-DADFT, 1] revealed the polyether to be more tolerable, achieving higher concns. in the liver and significantly lower concns. in the kidney. The lower renal drug levels are in keeping with the profound difference in the architectural changes seen in the kidney of rodents given 1 vs. those treated with 11.

IT 887471-65-OP 887471-66-IP

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L4 ANSWER 3 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses) (designing iron chelators that balance lipophilicity/nephrotoxicity problem)

RN 887471-65-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-(2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl)-4-methyl-, 1-methylethyl ester, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 887471-66-1 CAPLUS

CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-(2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl)-4-methyl-, ethyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 887471-64-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(designing iron chelators that balance lipophilicity/nephrotoxicity problem)

RN 887471-64-9 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-, 1-methylethyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 3 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR

THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 4 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:41680 CAPLUS

DOCUMENT NUMBER: 144:293049

TITLE:

Total synthesis of halipeptin A, a potent anti-inflammatory cyclodepsipeptide from a marine sponge

AUTHOR(S): Hara, Sousuke; Makino, Kazuishi; Hamada, Yasunasa
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, 263-8522, Japan

SOURCE: Tetrahedron Letters (2006), 47(7), 1081-1085

CODEN: TETLEA; ISSN: 0040-4039


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:293049

GI



AB Total synthesis of halipeptin A (1), a potent anti-inflammatory cyclodepsipeptide, was achieved through proline-catalyzed asym. α-oxidation, diastereoselective aldol reaction, silver cyanide-mediated esterification, and macrolactamization.

IT 474550-00-OP 878632-95-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(total synthesis of antiinflammatory cyclodepsipeptide halipeptin A)

RN 474550-00-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[(1S)-1-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-4,5-dihydro-4-methyl-, methyl ester, (4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 878632-95-2 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[(1S)-1-[(9H-fluoren-9-

L4 ANSWER 4 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ylmethoxy)carbonyl]amino]ethyl]-4,5-dihydro-4-methyl-, methyl ester,
(4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 5 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:417674 CAPLUS
DOCUMENT NUMBER: 143:125818

TITLE: Polyamine-Vectored Iron Chelators: The Role of Charge
AUTHOR(S): Bergeron, Raymond J.; Bharti, Neelam; Wiegand, Jan;
McManis, James S.; Yao, Hua; Prokai, Laszlo
CORPORATE SOURCE: Department of Medicinal Chemistry, University of
Florida, Gainesville, FL, 32610-0485, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(12),
4120-4137
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The utility of polyamines as vectors for the intracellular transport of
iron chelators is further described. Consistent with earlier results
with polyamine analogs, these studies underscore the importance of charge in
the design of polyamine-vectored chelators. Four polyamine conjugates
were synthesized (I-IV). These four mols. were evaluated in murine
leukemia L1210 cells for their impact on cell proliferation (48- and 96-h
IC50 values), their ability to compete with spermidine for the polyamine
transport apparatus (Ki), and their intracellular accumulation. The data
revealed that when neutral mols. (cargo fragments) were fixed to the
polyamine vector, the conjugates competed well with spermidine for
transport and were accumulated intracellularly to millimolar levels.
However, this was not the case when the cargo fragments were neg.


charged.
Metabolic studies of the polyamine-vectored (S)-4'-(HO)-DADFTs in rodents
indicated that not only did the expected deaminopropylation step occur,
but also a surprisingly high level of oxidative deamination at the
terminal primary nitrogens took place. Finally, the iron-clearing
efficiency of the (S)-4'-(HO)-DADFT conjugates was determined in a
bile-duct-cannulated rodent model. Attaching the ligand to a polyamine
vector had a profound effect on increasing the iron-clearing efficiency

of this chelator relative to its parent drug.

IT 847829-16-7P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT
(Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
(Uses)
(role of charge of polyamine-vectored iron chelators)

RN 847829-16-7 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[4-[4-[[[1,1-dimethylethoxy]carbonyl]amino]propyl]amino]butoxy]-2-hydroxyphenyl]-4,5-dihydro-4-methyl-, ethyl ester, trihydrochloride, (4S)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



● 3 HCl


IT 847829-15-6P 847829-19-OP 857941-15-2P
857941-17-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(role of charge of polyamine-vectored iron chelators)
RN 847829-15-6 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-, ethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847829-19-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[4-[[[5,9-bis[[1,1-dimethylethoxy]carbonyl]-16,16-dimethyl-14-oxo-13-oxa-5,9,13-triazasheptadec-1-yl]oxy]-2-hydroxyphenyl]-4,5-dihydro-4-methyl-, ethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


L4 ANSWER 5 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

—OBU-t


RN 857941-15-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[4-[4-[[[1,1-dimethylethoxy]carbonyl]amino]propyl]amino]butoxy]-2-hydroxyphenyl]-4,5-dihydro-4-methyl-, ethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857941-17-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[4-[4-[[[1,1-dimethylethoxy]carbonyl]amino]butoxy]-2-hydroxyphenyl]-4,5-dihydro-4-methyl-, ethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 96 THERE ARE 96 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 6 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:23847 CAPLUS
 DOCUMENT NUMBER: 142:291453
 TITLE: Polyamine-metal chelator conjugates
 INVENTOR(S): Bergeron, Raymond J., Jr.
 PATENT ASSIGNEE(S): University of Florida Research Foundation, Inc., USA
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023310	A2	20050317	WO 2004-US29318	20040909
WO 2005023310	A3	20050421		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004270261	A1	20050317	AU 2004-270261	20040909
CA 2538159	AA	20050317	CA 2004-2538159	20040909
EP 1667727	A2	20060614	EP 2004-783536	20040909
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK		US 2003-501341P	P 20030909
PRIORITY APPLN. INFO.:			WO 2004-US29318	W 20040909

OTHER SOURCE(S): MARPAT 142:291453
 AB Many metal chelators have polar or charged functional groups, which render them difficult to transport across a cell membrane. Polyamine-metal chelator conjugates of the invention are compds. comprising a first moiety which is a metal chelator and a second moiety which is a polyamine, where the polyamine moiety includes three or more nitrogen atoms which are capable of being pos. charged at physiol. pH. A conjugate of 1,2-Dimethyl-3-hydroxypyridin-4-one (L1) with spermine has been shown to accumulate in L1210 cells several hundred fold more than the unconjugated L1 chelator.
 IT 847829-16-7P
 RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (polyamine-metal chelator conjugates and uses in pharmacotherapy and radiotherapy and in imaging tissue and combination with other agents such as polyamine synthesis inhibitors)

L4 ANSWER 6 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




PAGE 1-B

—OBu-t

L4 ANSWER 6 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 847829-16-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[4-[[[3-[[[3-aminopropyl]amino]propyl]amino]butoxy]-2-hydroxyphenyl]-4,5-dihydro-4-methyl-, ethyl ester, trihydrochloride, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl

IT 847829-15-6P 847829-19-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (polyamine-metal chelator conjugates and uses in pharmacotherapy and radiotherapy and in imaging tissue and combination with other agents such as polyamine synthesis inhibitors)
 RN 847829-15-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-, ethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847829-19-0 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[4-[[[5,9-bis-[(1,1-dimethylethoxy)carbonyl]-16,16-dimethyl-14-oxo-15-oxa-5,9,13-triazaheptadec-1-yl]oxy]-2-hydroxyphenyl]-4,5-dihydro-4-methyl-, ethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 7 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:10316 CAPLUS
 DOCUMENT NUMBER: 142:261769
 TITLE: Total synthesis of halipten A: A potent antiinflammatory cyclic depsipeptide
 AUTHOR(S): Yu, Shouyun; Pan, Xianhua; Lin, Xianfeng; Ma, Dawei
 CORPORATE SOURCE: State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, Peop. Rep. China
 SOURCE: Angewandte Chemie, International Edition (2005), 44(1), 135-138
 CODEN: AIEF5; ISSN: 1433-7851
 PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:261769
 GI



AB The antiinflammatory drug halipten A (I) is a 17-membered cyclic depsipeptide. Key steps in the total synthesis of I included a borane-mediated aldol reaction and an asym. aza-Claisen rearrangement. The 14R-diastereomer of I was also synthesized, and thus, the stereochem. of natural product I was confirmed.
 IT 845817-56-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (total synthesis and stereochem. confirmation of antiinflammatory cyclic depsipeptide halipten A)
 RN 845817-56-3 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[[1S]-1-[[[9H-fluoren-9-ylmethoxy]carbonyl]amino]ethyl]-4,5-dihydro-4-methyl-, 2-propenyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 7 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L4 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:308425 CAPLUS
DOCUMENT NUMBER: 140:321719
TITLE: Process for producing optically active α -substituted cysteine or salt thereof, intermediate thereof, and process for producing the same
INVENTOR(S): Maruoka, Keiji; Ooi, Takashi; Inoue, Kenji
PATENT ASSIGNEE(S): Kaneka Corporation, Japan
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2004031163 A1 20040415 WO 2003-JP12565 20031001
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
AU 2003268706 A1 20040423 AU 2003-268706 20031001
EP 1548013 A1 20030629 EP 2003-748633 20031001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, RU, SK
US 2006069134 A1 20060330 US 2005-529039 20050324
PRIORITY APPLN. INFO.: JP 2002-288401 A 20021001
JP 2003-201787 A 20030725
WO 2003-JP12565 W 20031001

OTHER SOURCE(S): CASREACT 140:321719; MARPAT 140:321719
GI

L4 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Disclosed is a practical process for easily or industrially advantageously producing from an easily available inexpensive material an optically active α -substituted cysteine or salt thereof useful as an intermediate for medicines, etc. The process, which is for producing an optically active α -substituted cysteine of formula R3C*(NH2)(CH2SH)CO2H [C* = an asym. carbon atom; R3 = each (un)substituted linear, branched or cyclic C1-20 alkyl, linear, branched or cyclic C2-20 alkenyl, linear, branched or cyclic C2-20 alkynyl, linear, branched or cyclic C3-20 alkoxy-carbonyl, C7-30 aralkyl, or C4-30 heteroaralkyl], comprise converting a cysteine derivative into a thiazoline compound (I); R1 = each (un)substituted linear, branched, or cyclic C1-10 alkyl or C1-10 alkyldiaryl; R2 = each (un)substituted C6-30 aryl or linear, branched, or cyclic C1-20 alkyl], subjecting the compound I to a stereoselective substituent-introducing reaction with a compound R3-L (R3 = same as above; L = a leaving group) in the presence of the aid of an optically active quaternary ammonium salt, especially an axially asym. quaternary ammonium salt, as a catalyst to thereby obtain an optically active thiazoline compound (II); R1-R3 = same as above), and hydrolyzing the compound II. Thus, 2 mL toluene was added to 79.0 mg tert-Bu (R)-2-phenylthiazoline-4-carboxylate (III) (preparation given) and 2.74 mg an optically active quaternary ammonium salt [(S,S)-IV], treated with 37.3 μ L MeI, cooled to 0°, treated with 1 mL 50% aqueous KOH, and stirred until the compound III disappeared to give, m

L4 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
after workup and silica gel chromatog., 86% tert-Bu (R)-4-methyl-2-phenylthiazoline-4-carboxylate (V) (97% ee). The compd. V (1 g) and 10 g 4 N aq. HCl were added to glass vessel and refluxed until the compd. V disappeared. The reaction mixt. was concd. to approx. 1/6 of the original vol. under reduced pressure, codistd. with 5 mL toluene three times to give, after filtration of the pptd. crystals, washing with toluene, and drying under reduced pressure overnight, 88.0% (R)- α -methyl-L-cysteine hydrochloride.

IT 679004-90-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for producing optically active α -substituted cysteine or salt thereof by stereoselective alkylation of thiazolinecarboxylic acid

esters in presence of optically active quaternary ammonium salt)
RN 679004-90-1 CAPLUS
CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-phenyl-, 1,1-dimethylethyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 679004-92-3P 679004-93-4P 679004-94-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(process for producing optically active α -substituted cysteine or salt thereof by stereoselective alkylation of thiazolinecarboxylic acid

esters in presence of optically active quaternary ammonium salt)
RN 679004-92-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-phenyl-4-(phenylmethyl)-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 679004-93-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 4-ethenyl-4,5-dihydro-2-phenyl-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 679004-94-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-phenyl-4-(2-propynyl)-, ethyl ester, (4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:931347 CAPLUS
 DOCUMENT NUMBER: 139:381748
 TITLE: Synthesis of 2-alkylcysteines and 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives
 INVENTOR(S): Chanda, Bhanu M.; Cherian, Joseph; Chorghade, Mukund S.; Gimi, Rayomand H.; Gurjar, Mukund K.; McDonnell, Peter D.; Mhaskar, Sunil V.; Mohapatra, Dedendara K.; Wolstenhorne-Hogg, Paul
 PATENT ASSIGNEE(S): Genzyme Corporation, USA
 SOURCE: PCT Int. Appl., 168 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097622	A2	20031127	WO 2003-US15553	20030515
WO 2003097622	A3	20040408		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003220504	A1	20031127	US 2003-439286	20030515
US 6875883	B2	20050405		
AU 2003247374	A1	20031202	AU 2003-247374	20030515
US 2003225287	A1	20031204	US 2003-439313	20030515
US 6903220	B2	20050607		
US 2003229231	A1	20031211	US 2003-438745	20030515
US 6861532	B2	20050301		
US 2003236434	A1	20031225	US 2003-438744	20030515
US 6794515	B2	20040921		
US 2003236404	A1	20031225	US 2003-438757	20030515
US 2003236435	A1	20031225	US 2003-439282	20030515
US 6878828	B2	20050412		
US 2003236426	A1	20031225	US 2003-439342	20030515
US 6846958	B2	20050125		
US 2004002613	A1	20040101	US 2003-439341	20030515
US 6875882	B2	20050405		
US 2004006224	A1	20040108	US 2003-439265	20030515
US 7038073	B2	20060502		
US 2004024224	A1	20040205	US 2003-438770	20030515
US 7002036	B2	20060221		
US 2004082796	A1	20040429	US 2003-439263	20030515
US 6982335	B2	20060103		
EP 1529037	A2	20050511	EP 2003-753073	20030515
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

L4 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005538950 T2 20051222 JP 2004-505355 20030515
 US 2005209462 A1 20050922 US 2004-8084 20041209
 US 2006069265 A1 20060330 US 2005-85824 20050321
 US 2006142586 A1 20060629 US 2005-287891 20051128
 US 2006167267 A1 20060727 US 2005-305305 20051216
 PRIORITY APPLN. INFO.: US 2002-380878P P 20020515


US 2002-380880P P 20020515
 US 2002-380894P P 20020515
 US 2002-380895P P 20020515
 US 2002-380903P P 20020515
 US 2002-380909P P 20020515
 US 2002-380910P P 20020515
 US 2002-381012P P 20020515
 US 2002-381013P P 20020515
 US 2002-381017P P 20020515
 US 2002-381021P P 20020515
 US 2002-392833P P 20020627
 US 2003-438770 A3 20030515
 US 2003-439265 A3 20030515
 US 2003-439313 A1 20030515
 US 2003-439342 A3 20030515
 WO 2003-US15553 W 20030515

OTHER SOURCE(S): CASREACT 139:381748

AB The invention provides methods of preparing 2-alkylcysteine derivs., many of which can be performed stereoselectively, and a class of iron-chelating agents related to desferriethiocin, all of which contain a thiazoline ring. The 2-alkylcysteines are represented by R2SCH2CR1R4CO2R3 [R1 = NH2, alkylamino or (hetero)arylamino; R2, R3 = H, (un)substituted alkyl or (hetero)aryl; R4 = (un)substituted alkyl]. In examples, 2-methylcysteine was prepared by addition reaction of Me acrylate with bromamine-T, ring cleavage of N-tosyl-2-carbomethoxy-2-methylaziridine with thioacetic acid, and reaction with NaOMe/MeOH and HBr/AcOH/phenol. Treatment of Et3N (S)-2-methylcysteine with 2,4-dihydroxybenzoinitrile in EtOH containing afforded 87.6% 4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid. 625088-61-1P
 IT RL: SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


(synthesis of alkylcysteines and (hydroxyphenyl)alkylthiazolinecarboxylic acids)
 RN 625088-61-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-(4-methoxyphenyl)-4-(phenylmethyl)-, 1-methylethyl ester, (4S)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.



OK
 R⁷-C, alkyl
 benzyl group
 G-aryl/alkyl


L4 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(Reactant or reagent)
(prepn. of heterocyclic compds. and their use for inhibiting
β-amyloid peptide release)
RN 213024-92-1 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[(3,5-difluorophenyl)methyl]-4,5-dihydro-4-
methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

OTHER SOURCE(S): MARPAT 138:90080
GI




AB Disclosed are modified heterocyclic di- and tripeptide analogs which inhibit β -amyloid peptide release and/or its synthesis and, accordingly, have utility in treating Alzheimer's disease. Comps. of formula R1NHCH(R2)(CONHCH(R3)R4)pCONHCH(R3)(NR4) [R1 = H or acyl; R2, R3, R6 (un)substituted alk(en)(yn)yl, cycloalkyl, (hetero)aryl, heterocyclyl; p = 0 or 1; R3 and R4 combine to form a heterocyclic ring, which may be substituted] are claimed. Also disclosed are pharmaceutical comps. comprising a compound which inhibits β -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical comps. Title comps., e.g. 1, were prepared in a multistep synthesis and inhibited β -amyloid peptide production by at least 30% as compared to control.

IT 21:3024-92-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

14 ANSWER 11 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:928795 CAPLUS
DOCUMENT NUMBER: 138:368655
TITLE: Thiazoline ring formation from 2-methylcysteines and
2-halomethylalanines
AUTHOR(S): Kedrowski, Brant L.; Heathcock, Clayton H.
CORPORATE SOURCE: Dep. Chem., Center New Directions Organic Synthesis,
Univ. California, Berkeley, CA, 94720, USA
SOURCE: Heterocycles (2002). 58, 601-634
CODEN: HETCYAM; ISSN: 0385-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:368655
AB A systematic survey of conditions and substrates for the formation of
2,4,4-trisubstituted thiazoline rings is presented. The substitution
patterns of these thiazolines is particularly relevant for the synthesis
of the tanzolone, mirabazone, and thiagazole classes of natural
products,
which contain a linear array of these heterocycles. Methods for the
formation of these thiazolines from 2-methylcysteines and
2-halomethylalanines are discussed.
IT 158252-58-5P
RL: SPN (Synthetic preparation): PREP (Preparation)
(preparation of, as a tanzolone synthon; preparation of
2,4,4-trisubstituted
thiazoline chiral natural product synthons from 2-methylcysteines and
2-halomethylalanines)
RN 158252-58-5 CAPLUS
CM 4-Thiazolocarboxylic acid, 4,5-dihydro-4-methyl-2-(1-methylethyl)-,
methyl
ester. (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 17 of 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:835624 CAPLUS
 DOCUMENT NUMBER: 139:6779
 TITLE: Product class 17: thiazoles
 AUTHOR(S): Kikelj, D.; Uribe, U.
 CORPORATE SOURCE: Fac. Pharm., University Ljubljana, Slovenia
 SOURCE: Science of Synthesis (2002), 11, 627-833
 CODEN: SSCYJ9
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal: General Review
 LANGUAGE: English
 AB A review of synthetic methods to prepare thiazoles as well as reactive
 IT modifications of thiazole moieties.
 533887-30-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (review of preparation of thiazoles and reactions thereof)
 RN 533887-30-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(1S)-1-(acetyloxy)ethyl]-4,5-dihydro-4-
 hydroxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1224 THERE ARE 1224 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 13 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:565737 CAPLUS

DOCUMENT NUMBER: 137:353288

TITLE: Structural revision of halipeptins: synthesis of the thiazoline unit and isolation of halipeptin C

AUTHOR(S): Della Monica, Carmela; Randazzo, Antonio; Bifulco, Giuseppe; Cimino, Paola; Aquino, Maurizio; Izzo, Irene; De Riccardis, Francesco; Gomez-Paloma, Luigi

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Università di Salerno, Fisciano, 84084, Italy

SOURCE: Tetrahedron Letters (2002), 43(33), 5707-5710

CODEN: TELEAV; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:353288

AB The structural revision of the anti-inflammatory marine metabolites halipeptin A and B along with the isolation of the new related product halipeptin C are reported. In particular, the heterocyclic portion of the mol., incorrectly assigned as an oxazetidine ring, has now been characterized as a thiazoline unit by comparison of the spectral data of the natural products with an appropriate synthetic model

2-[1-(S)-tert-butoxycarbonylaminoethyl]-4-(R)-methyl-4,5-dihydrothiazole-4-carboxylic acid Me ester. GIAO calculated ¹³C NMR chemical shifts for oxazetidine and thiazoline model compds. provide addnl. support to the revised structure.

IT 474550-00-OP

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(preparation of butoxycarbonyl methyl-4,5-dihydrothiazolecarboxylic acid

Me ester from methylcysteine via coupling for determination of halipeptins mol. structure)


RN 474550-00-0 CAPLUS

CN 4-Thiazolecarboxylic acid,

2-[(1S)-1-[[[1,1-dimethylethoxy]carbonyl]amino]

ethyl]-4,5-dihydro-4-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR

THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:723707 CAPLUS

DOCUMENT NUMBER: 136:50899

TITLE: Structure-activity relationship of the antimycoplasma antibiotic micacoccidin - a preliminary study

AUTHOR(S): Ino, Akira; Kobayashi, Shinobu; Ueda, Kazuo; Hida, Shigetada; Hayase, Yoshio

CORPORATE SOURCE: Aburahi Laboratories, Shionogi and Co., Ltd., Shiga, 520-3423, Japan

SOURCE: Journal of Antibiotics (2001), 54(9), 753-756

CODEN: JANTAJ; ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The antimycoplasma activities of micacoccidin derivs. were studied to further understand the relationship between structure and activity. The isolation, determination structure, and total synthesis of micacoccidin

(1), which corresponds to the metal-free ligand A (2) were described. The role of bulkiness of the substituents and the presence of hydrogen atom required for forming hydrogen bond are crucial for showing the activity. The spatial structure of micacoccidin (1) in solution was held with three intramol. hydrogen bonds to take a folded conformation resembling that of micacoccidin A (2). The almost equally potent activities of 1 and 2 was presumably ascribed to their similar spatial conformations. The potency of activities was dependent on the ability adopt folded conformation. Conformation change of the activity caused by modification of the C-14 secondary alc. moiety was probably due to its control location in the

mol. Reduced activities of 10S isomers were also rationalized by the difficulty in taking folded conformation. The evidence accumulated will clarify the action mechanism of the anti-mycoplasma activity by micacoccidin, and facilitate the development of new antimycoplasma agents.

IT 194733-82-9 194733-84-1 194733-87-4

194733-89-6 194733-90-9 194733-92-1

383198-10-5 383198-11-6 383198-12-7

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(structure-activity relationship of antimycoplasma antibiotic

micacoccidin - a preliminary study)

RN 194733-82-9 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

L4 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



RN 194733-84-1 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-methoxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 194733-87-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-methoxymethoxy)-6-pentylphenyl]-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-(methoxymethoxy)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 194733-89-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-(methoxymethoxy)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 194733-90-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 194733-92-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, (4-chlorophenyl)methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383198-10-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 383198-11-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4S)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383198-12-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4S)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 REFERENCE COUNT: 14
 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 15 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:155247 CAPLUS
 DOCUMENT NUMBER: 134:353194
 TITLE: Synthetic studies of thiazoline and thiazolidine-containing natural products. Part 3: Total synthesis and absolute configuration of the siderophore yersiniabactin
 AUTHOR(S): Ino, A.; Murabayashi, A.
 CORPORATE SOURCE: Koka, Aburahi Laboratories, Shionogi and Co. Ltd, 520-3423, Shiga, Japan
 SOURCE: Tetrahedron (2001), 57(10), 1897-1902
 CODEN: TETRA; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:353194
 GI




AB Total synthesis of yersiniabactin (I), a siderophore from cultures of the bacterium *Yersinia enterocolitica*, was accomplished. Chirality at the readily racemizable C-9 carbon was preserved during cyclization of β -hydroxythioamide by means of Burgess reagent leading to thiazoline. Based on its synthesis, the absolute configuration of natural yersiniabactin has been determined as 9R, 10RS, 12R, 13S and 19S.
 IT 208585-91-5P 338461-22-6P 338461-24-8P
 338461-25-9P 338461-27-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (total synthesis and absolute configuration of the siderophore yersiniabactin)
 RN 208585-91-5 CAPLUS
 CN L-threo-Pentitol, 1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-S-[(4-methoxyphenyl)methyl]-2-methyl-5-thio- (9CI) (CA INDEX NAME)]
 Absolute stereochemistry. Rotation (-).


L4 ANSWER 15 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CMF C2 H F3 O2



RN 338461-25-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxyphenyl)-4-thiazolyl]-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 338461-27-1 CAPLUS
 CN L-threo-Pentitol, 1,2,4,5-tetradecy-4-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-[(6-nitro-2-pyridinyl)dithio]- (9CI) (CA INDEX NAME)]
 Absolute stereochemistry.




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L4 ANSWER 15 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 338461-22-6 CAPLUS
 CN L-threo-Pentitol, 1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-5-thio- (9CI) (CA INDEX NAME)]
 Absolute stereochemistry. Rotation (-).





RN 338461-24-8 CAPLUS
 CN L-threo-Pentitol, 4-amino-1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-2-methyl-5-thio-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 338461-23-7
 CMF C12 H22 N2 O3 S2
 Absolute stereochemistry.



CM 2
 CRN 76-05-1


L4 ANSWER 16 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:362495 CAPLUS
 DOCUMENT NUMBER: 133:163962
 TITLE: Fourier transform infrared and circular dichroism spectroscopic studies of hydrogen bonding in micacocidin A and micacocidin in dilute CH2Cl2 or CHCl3 solution
 AUTHOR(S): Takasuka, M.; Kobayashi, S.; Ino, A.; Iwata, T.; Hayase, Y.
 CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi and Co., Ltd., Osaka, 553-0002, Japan
 SOURCE: Vibrational Spectroscopy (2000), 23(2), 243-251
 CODEN: VISPEK; ISSN: 0924-2031
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB FTIR spectra of micacocidin A (I), which is a Zn complex antibiotic, the metal-free ligand micacocidin (II), its derivative, and their related compounds were measured in dilute CH2Cl2 solution in order to elucidate the conformations of I and II in solution. Curve analysis of the spectra to separate overlapping absorption bands showed that I forms dimers due to two strong intermolecular hydrogen bonds between a hydroxy group and the phenolate anion and II exists in a folded conformation with three rings formed by intramolecular hydrogen bonds between phenolic, aliphatic and carboxylic OH groups and the N atoms of thiazoline, another thiazoline and thiazolidine, resp. The concentration and temperature dependencies of CD spectra of I were measured in CHCl3 and CH3OH solutions and CH3CN solution, resp., in order to confirm the formation

L4 ANSWER 16 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 of the dimers of 1 in these solvents. The variation of the CD band by
 addn. of ZnCl₂ to 11 was also measured in CH₃OH soln. 11 was shown to be
 more easily transformed to 1 by Zn²⁺ ion in the soln.
 IT 194733-80-7 194733-83-0 194733-88-5
 194733-90-9 208585-93-7
 RL: PRP (Properties)
 (FTIR and CD spectra of hydrogen bonding in micacocidin A and
 micacocidin in dilute CH₂Cl₂ or CHCl₃ solution)
 RN 194733-80-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-(acetyloxy)-2-[(2R,4R)-2-[(4R)-2-[2-
 (acetyloxy)-6-pentylphenyl]-4,5-dihydro-4-thiazolyl]-3-methyl-4-
 thiazolidinyl]-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester,
 (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 194733-83-0 CAPLUS
 CN 4-Thiazolecarboxylic acid,
 2-[(2S)-2-[(4-chlorophenyl)methoxy]-2-[(2R,4R)-
 2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-
 thiazolidinyl]-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester,
 (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 16 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




RN 208585-93-7 CAPLUS
 CN L-threo-Pentitol,
 1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-
 methyl-2-thiazolyl]-4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-5-S-[[4-
 methoxyphenyl)methyl]-2-methyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 16 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 194733-88-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-[(2-
 (methoxymethoxy)-6-pentylphenyl]-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-
 hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester,
 (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 194733-90-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-[(2-
 hydroxy-6-pentylphenyl]-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-
 1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester, (4S)-
 (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:763870 CAPLUS
 DOCUMENT NUMBER: 132:15624
 TITLE: Drugs for enhancing patients' sensitivity against
 drug-resistant pathogenic microorganisms
 INVENTOR(S): Nakamura, Takashi; Yamano, Yoshinori; Seo, Syujiro
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961021	A1	19991202	WO 1999-JP2596	19990519
W: JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			JP 1998-143949	A 19980526

OTHER SOURCE(S): MARPAT 132:15624
 GI



AB Thiazole derivs. shown by Markush structure (I) where R1, R2, and R3
 represent a large number of substituents described in the claim, are
 especially effective against drug-resistant Pseudomonas.


IT 194733-90-9
 RL: BAC (Biological activity or effector, except adverse): BSU
 (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES
 (Uses)
 (thiazole derivs. for controlling drug-resistant pathogenic
 microorganisms)

RN 194733-90-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-
 hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-
 1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester, (4S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 17 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:548673 CAPLUS
DOCUMENT NUMBER: 131:322458
TITLE: Synthetic studies of thiazoline and thiazolidine-containing natural products. 2. Total synthesis of the antimycoplasmal antibiotic micacocidin
AUTHOR(S): Ino, Akira; Hasegawa, Yasushi; Murabayashi, Akira
CORPORATE SOURCE: Aburahi Laboratories, Shionogi and Co., Ltd., Shiga, 520-3423, Japan
SOURCE: Tetrahedron (1999), 55(34), 10293-10294
CODEN: TETRA; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 131:322458
AB Synthesis of the right half of micacocidin (segment B) and subsequent completion of total synthesis of the antimycoplasmal antibiotic micacocidin is described. The desired S-configuration at C-14 secondary carbinol was obtained by stereoselective reduction of the preceding ketone in accordance with the Cram rule. Condensation of two labile segments, A and B, was achieved in the presence of potassium acetate. The chiral center at C-10 was finally isomerized to the natural configuration through formation of the Zn complex.
IT 194733-82-9P, Micacocidin methyl ester 208585-87-9P
208585-89-1P 208585-91-5P 208585-93-7P
208585-95-9P 208586-06-5P 249271-59-8P
249271-60-1P 249271-62-3P 249271-65-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
RN (total synthesis of the antimycoplasmal antibiotic micacocidin)
CN 194733-82-9 CAPLUS
4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208585-87-9 CAPLUS

L4 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-[(4R,5S)-4-[(mercaptomethyl)-2-oxo-5-oxazolidinyl]-1-methylethyl]-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 208585-89-1 CAPLUS
CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-[(4R,5S)-4-[(4-methoxyphenyl)methyl]thio]methyl]-2-oxo-5-oxazolidinyl]-1-methylethyl]-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 208585-91-5 CAPLUS
CN L-threo-Pentitol, 1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-S-[(4-methoxyphenyl)methyl]-2-methyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 208585-93-7 CAPLUS
CN L-threo-Pentitol, 1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-4-[(1,1-dimethylethoxy)carbonyl]meth-

L4 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued).


methoxyphenyl)methyl]-2-methyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 208585-95-9 CAPLUS
CN L-threo-Pentitol, 1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-S-[(4-methoxyphenyl)methyl]-2-methyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 208586-06-5 CAPLUS
CN L-threo-Pentitol, 1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-4-[(1,1-dimethylethoxy)carbonyl]amino]-5-S-[(4-methoxyphenyl)methyl]-2-methyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 249271-59-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S,3R)-3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-[[[(4-methoxyphenyl)methyl]thio]-1,1-dimethylbutyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 249271-60-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S,3R)-3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-2-hydroxy-1,1-dimethyl-4-[(3-nitro-2-pyridinyl)dithio]butyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 249271-62-3 CAPLUS
 CN L-threo-Pentitol, 1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-2-methyl-4-(methylamino)-5-thio-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 208585-97-1
 CMF C13 H24 N2 O3 S2


L4 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 18 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




CH 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 249271-65-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-2-[2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-6-pentylphenyl]-4,5-dihydro-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 249271-61-2P


RL: SPN (Synthetic preparation): PREP (Preparation)
 (total synthesis of the antimycoplasm antibiotic micacocidin)

RN 249271-61-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[1-[(1S,7aR)-dihydro-5,5-dimethyl-3-oxo-1H,3H,5H-thiazolo[3,4-c]oxazol-1-yl]-1-methylethyl]-4,5-dihydro-4-methyl-,

L4 ANSWER 19 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:548672 CAPLUS
 DOCUMENT NUMBER: 131:336849
 TITLE: Synthetic studies of thiazoline and thiazolidine-containing natural products. 1. Phosphorus pentachloride-mediated thiazoline construction reaction
 Ino, Akira; Murabayashi, Akira
 CORPORATE SOURCE: Aburahi Laboratories, Shionogi and Co., Ltd., Shiga, 520-3423, Japan
 SOURCE: Tetrahedron (1999), 55(34), 10271-10282
 CODEN: TETRA8; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:336849
 GI



AB Phosphorus pentachloride effectively mediates the cyclization of N-acylcysteamine derivs. giving rise to thiazoline rings. Sterically hindered thiazoline analogs were constructed and the left half fragment I of micacocidin, a unique antimycoplasm antibiotic, was efficiently synthesized via the PCl5 mediated cyclization of N-acylcysteamine derivs.
 IT 153060-83-4P
 RL: SPN (Synthetic preparation): PREP (Preparation)
 (preparation of thiazolines via PCl5 mediated cyclization of N-acylcysteamines)
 RN 153060-83-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 20 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1998:608608 CAPLUS
 DOCUMENT NUMBER: 129:245485
 TITLE: Preparation of heterocyclic compounds and their use for inhibiting β -amyloid peptide release
 INVENTOR(S): Thorsett, Eugene D.; Porter, Warren J.; Nissen, Jeffrey S.; Latimer, Lee H.; Audia, James E.; Droste, James J.
 PATENT ASSIGNEE(S): Athena Neurosciences, Inc., USA; Eli Lilly & Co.
 SOURCE: PCT Int. Appl., 392 pp.
 CODEN: PIXXDZ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9838177	A1	19980903	WO 1998-US3373	19980227
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GR, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, ML, MR, NE, SN, TD, TG			
ZA 9801627	A	19991005	ZA 1998-1627	19980226
CA 2278674	AA	19980903	CA 1998-2278674	19980227
AU 9866622	A1	19980918	AU 1998-66622	19980227
EP 968198	A1	20000105	EP 1998-908637	19980227
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR 9902071	T2	20000121	TR 1999-2071	19980227
BR 9807876	A	20000229	BR 1998-7876	19980227
JP 200151107	T2	20010828	JP 1998-537732	19980227
WO 9904016	A	19991018	NO 1999-4016	19990819
PRIORITY APPL. INFO.:			US 1997-808263	A1 19970228
			WO 1998-US3373	W 19980227

OTHER SOURCE(S): MARPAT 129:245485
 GI




L4 ANSWER 21 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1998:330820 CAPLUS
 DOCUMENT NUMBER: 129:67621
 TITLE: Total synthesis of the antimycoplasma antibiotic micacocidin
 AUTHOR(S): Ino, Akira; Hasegawa, Yasushi; Murabayashi, Akira
 CORPORATE SOURCE: Aburahi Laboratories, Shionogi and Co., Ltd., Shiga, 520-3423, Japan
 SOURCE: Tetrahedron Letters (1998), 39(21), 3509-3512
 CODEN: TELEAV; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 129:67621
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A total synthesis of the antimycoplasma antibiotic micacocidin (I) is described. Construction of sterically hindered thiazoline II was achieved by a phosphorus pentachloride-mediated cyclization reaction of S-protected arylcysteine III (PMB = CH₂C₆H₄OMe-4), and I with desired chirality at C-10 was favorably obtained from diastereomeric mixture IV through formation of the Zn complex V.
 IT 194733-82-9P, Micacocidin methyl ester 208585-87-9P
 208585-89-1P 208585-91-5P 208585-93-7P
 208585-95-9P 208585-98-2P 208586-06-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (total synthesis of the antimycoplasma antibiotic micacocidin via chelation-controlled isomerization)
 RN 194733-82-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208585-87-9 CAPLUS

L4 ANSWER 20 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

AB Disclosed are modified heterocyclic di- and tripeptide analogs which inhibit β -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compns. comprising a compound which inhibits β -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compns. Title compds., e.g. I, were prepared in a multistep synthesis and inhibited β -amyloid peptide production by at least 30% as compared to control.
 IT 213024-92-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heterocyclic compds. and their use for inhibiting β -amyloid peptide release)
 RN 213024-92-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(3,5-difluorophenyl)methyl]-4,5-dihydro-4-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT


L4 ANSWER 21 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-[(1-[(4R,5S)-4-[(mercaptomethyl)-2-oxo-5-oxazolidinyl]-1-methylethyl]-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 208585-89-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-[(1-[(4R,5S)-4-[(4-methoxyphenyl)methyl]thio]methyl]-2-oxo-5-oxazolidinyl]-1-methylethyl]-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 208585-91-5 CAPLUS
 CN L-threo-Pentitol, 1,2,4-trideoxy-2-[(1S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-5-thiazolyl]-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-S-[(4-methoxyphenyl)methyl]-2-methyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 208585-93-7 CAPLUS
 CN L-threo-Pentitol, 1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-5-thio- (9CI) (CA INDEX NAME)

1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-5-thio- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methoxyphenyl)methyl]-2-methyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 208585-95-9 CAPLUS

CN L-threo-Pentitol,
1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-

methyl-2-thiazolyl]-4-[(1,1-dimethylethoxy)carbonyl]methylamino]-2-methyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 208585-98-2 CAPLUS


CN L-threo-Pentitol,
1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-2-methyl-4-(methylamino)-5-thio-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 208585-97-1

CMF C13 H24 N2 O3 S2

Absolute stereochemistry.



L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

1997:542437 CAPLUS

127:205400

TITLE:

Preparation of micacoccidin derivatives as antibacterials, antifungals, coccidiostats, and immunosuppressants

INVENTOR(S):

Hayase, Yoshio; Kobayashi, Shinobu; Ueda, Kazuo; Hidaaka, Shigetada

PATENT ASSIGNEE(S):

Shionogi & Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729096	A1	19970814	WO 1997-JP266	19970204
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 406080	B	20000921	TW 1997-86101254	19970203
CA 2244901	AA	19970814	CA 1997-2244901	19970204
AU 9715584	A1	19970828	AU 1997-15584	19970204
CN 1215394	A	19990428	CN 1997-193647	19970204
CN 1082956	B	20020417		
EP 976741	A1	20000202	EP 1997-901828	19970204
R: CH, DE, ES, FR, GB, IT, LI, SE				
US 6004952	A	19991221	US 1998-117734	19980805
PRIORITY APPL. INFO.:			JP 1996-44243	A 19960205
			WO 1997-JP266	W 19970204

GI

L4 ANSWER 21 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 208586-06-5 CAPLUS

CN L-threo-Pentitol,
1,2,4-trideoxy-2-[(4S)-4,5-dihydro-4-(methoxycarbonyl)-4-methyl-2-thiazolyl]-4-[(1,1-dimethylethoxy)carbonyl]amino]-3-O-[(1,1-dimethylethyl)dimethylsilyl]-5-S-[(4-methoxyphenyl)methyl]-2-methyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; R1 = COOR4, CONR5R6, CO-R7-OR, etc.; R4 = H, OH, (un)substituted alkyl, (un)substituted alkoxy, etc.; R5, R6 = OH, (un)substituted alkoxy, etc.; R7 = α-amino acid residue; R = H, alkyl; R2 = H, (un)substituted alkyl, (un)substituted aralkyl, (un)substituted heteroaryl, etc.; R3 = H, OR8, O; R8 = H, (un)substituted alkyl, (un)substituted heteroarylalkyl, etc.] are prepared. Thus, micacoccidin in CH2Cl2 was treated with 1N HCl to give the title compound

II,

which had an IC50 of 6.3 μg/mL against *Candida albicans*.

IT 194733-80-7P 194733-82-9P 194733-84-1P

194733-91-OP

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of micacoccidin derivs. as antibacterials, antifungals, coccidiostats, and immunosuppressants)

RN 194733-80-7 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-(acetyloxy)-2-[(2R,4R)-2-[(4R)-2-[(2-acetyloxy)-6-pentylphenyl]-4,5-dihydro-4-thiazolyl]-3-methyl-4-thiazolidinyl]-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 194733-82-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194733-84-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-methoxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


PAGE 1-B

-Cl

IT 194733-81-8P 194733-83-0P 194733-85-2P
 194733-86-3P 194733-87-4P 194733-88-5P
 194733-89-6P 194733-90-9P 194733-92-1P
 194733-93-2P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of micacocidin derivs. as antibacterials, antifungals,
 cocciostats, and immunosuppressants)


RN 194733-81-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[2-[(2-[2-[(4-chlorophenyl)methoxy]-6-pentylphenyl]-4,5-dihydro-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, [2R-[2a(R*),4a[S*(S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194733-83-0 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(4-chlorophenyl)methoxy]-2-[(2R,4R)-


L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 194733-91-0 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[2-[(4-chlorophenyl)methoxy]-2-[2-[(2-[4-chlorophenyl)methoxy]-6-pentylphenyl]-4,5-dihydro-4-thiazolyl]-3-methyl-4-thiazolidinyl]-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, (4-chlorophenyl)methyl ester, [2R-[2a(R*),4a[S*(S*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194733-85-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[2-[(4,5-dihydro-2-(2-methoxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-1,1-dimethyl-2-(3,3,3-trifluoro-2-methoxy-1-oxo-2-phenylpropoxy)ethyl]-4,5-dihydro-4-methyl-, methyl ester, [2R-[2a(R*),4a[1(S*),2S*(S*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 194733-86-3 CAPLUS


L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(4R,4S)-dihydro-2-(2-methoxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-1,1-dimethyl-2-oxoethyl]-4,5-dihydro-4-methyl-, methyl ester, [2R-[2 α (R'),4 α (S')]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194733-87-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-(methoxymethoxy)-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-(methoxymethoxy)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 194733-88-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-(methoxymethoxy)-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 194733-89-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-(methoxymethoxy)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 194733-90-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methoxymethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 194733-92-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, (4-chlorophenyl)methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 194733-93-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(2S)-2-[(4-chlorophenyl)methoxy]-2-[(4,5-dihydro-2-(2-hydroxy-6-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, (4-chlorophenyl)methyl ester, [2R-[2 α (R'),4 α (S')]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 23 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1996:703670 CAPLUS
 DOCUMENT NUMBER: 126:6490
 TITLE: Chemical structure and total synthesis of new antimycoplasma antibiotic micacocidin
 AUTHOR(S): Ino, Akira; Kobayashi, Shinobu; Hidaka, Shigetada; Kawamura, Yoshihiro; Ozaki, Mamoru; Hayase, Yoshio; Takeda, Reiji; Murabayashi, Akira
 CORPORATE SOURCE: ABURAHAI LABORATORIES SHIONOGI and CO., LTD., Japan
 SOURCE: Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1996), 38th, 121-126
 CODEN: TYKYDS
 PUBLISHER: Nippon Kagakkai
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 GI



AB Antimycoplasma antibiotic micacocidin (I) is manufactured with soil Pseudomonas sp. 57-250 and purified from the fermentation broth by chromatog. Zn²⁺ enhanced the production of I. Chemical synthesis of I was given.
 IT 183621-84-3P 183621-85-4P 183621-89-8P
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of)
 RN 183621-84-3 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-[1-[4-[[[4-methoxyphenyl]methyl]thio]methyl]-3-methyl-2-oxo-5-oxazolidinyl]-1-methylethyl]-4-methyl-, methyl ester, [4R-[4a,5a(5*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1995:657309 CAPLUS
 DOCUMENT NUMBER: 123:83804
 TITLE: Total synthesis of thiangazole, a novel naturally occurring HIV-1 inhibitor from Polyangium sp
 AUTHOR(S): Boyce, Richard J.; Mulqueen, Gerard C.; Pattenden, Gerald
 CORPORATE SOURCE: Dep. Chemistry, Nottingham Univ., Nottingham, NG7 2RD, UK
 SOURCE: Tetrahedron (1995), 51(26), 7321-30
 CODEN: TETRA8; ISSN: 0040-4020
 PUBLISHER: Pergamon
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 123:83804
 GI




AB The total synthesis of the cinnamyl-oxazole substituted tris-thiazoline containing metabolite (-)-thiangazole is described. The synthesis is based on elaboration of the R-2-methylcysteine derived bis-thiazoline nitrile I and oxazole II intermediates, followed by a cyclocondensation reaction between I and II, and treatment of the resulting tris-thiazoline oxazole ester with methylamine.
 IT 157770-61-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (total synthesis of thiangazole)
 RN 157770-61-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-(2-phenylethenyl)-, methyl ester, [R-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L4 ANSWER 23 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 183621-85-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-[1-[4-(mercaptomethyl)-3-methyl-2-oxo-5-oxazolidinyl]-1-methylethyl]-4-methyl-, methyl ester, [4R-[4a,5a(5*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183621-89-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[2-[2-[4,5-dihydro-2-(2-hydroxy-5-pentylphenyl)-4-thiazolyl]-3-methyl-4-thiazolidinyl]-2-hydroxy-1,1-dimethylethyl]-4,5-dihydro-4-methyl-, methyl ester, [2R-[2a(R*),4a(5*(S*))]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 25 OF 41 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1995:657308 CAPLUS
 DOCUMENT NUMBER: 123:83058
 TITLE: Naturally occurring 4-methylthiazolines. A total synthesis of (-)-[4R,4'S]-didehydromirabazone A
 AUTHOR(S): Boyce, Richard J.; Pattenden, Gerald
 CORPORATE SOURCE: Dep. Chemistry, Nottingham Univ., Nottingham, NG7 2RD, UK
 SOURCE: Tetrahedron (1995), 51(26), 7313-20
 CODEN: TETRA8; ISSN: 0040-4020
 PUBLISHER: Pergamon
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The total synthesis of the 4-methylthiazoline-based natural product didehydromirabazone A, produced by the blue green alga Scytonema mirabile, shows that its stereostructure is (4R,4'S).
 IT 158252-58-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (total synthesis and absolute configuration of natural didehydromirabazone A)
 RN 158252-58-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-(1-methylethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1995:264543 CAPLUS
 DOCUMENT NUMBER: 122:56038
 TITLE: Thiazole and oxazole-based β 3-adrenergic receptor agonists
 INVENTOR(S): Sher, Philip M.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
 SOURCE: U.S., 20 pp
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5321036	A	19940614	US 1993-15940	19930210
PRIORITY APPLN. INFO.:			US 1993-15940	19930210

OTHER SOURCE(S): MARPAT 122:56038
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Comps. having the formula I and pharmaceutically acceptable salts thereof, where $R_1 = CR_7R_8(CH_2)_m$, R_3 is $(CH_2)_n$ or in the case where R_2 is II , R_3 in addition to the above may be $(CH_2)_pCR_7'(COR_4)$; R_4 is hydroxy, alkoxy, amino, alkylamino or dialkylamino; R_5 is hydrogen fluorine, chlorine, bromine, iodine, CN, CF₃, lower alkyl, lower alkoxy, cycloalkyl or aryl; R_6 is lower alkyl, cycloalkyl or aryl; R_7 , R_7' , R_8 and R_8' may together be CH_2CH_2 ; Z is hydrogen or $ACH(OH)CH_2$; m is an integer of 1 or 2; n is zero or an integer of 1 to 6; and p is an integer of 1 to 5. These comds. are β 3-adrenergic receptor agonists (no data) and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.


IT 159877-50-6P
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of β 3-adrenergic receptor agonists)

RN 159877-50-6 CAPLUS
 CN 4-Thiazolecarboxylic acid,
 2-[2-[(1,1-dimethylethoxy)carbonyl]amino]propyl
 1]-4,5-dihydro-4-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 27 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 158850-80-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-phenyl-, ethyl ester,
 (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158850-81-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-phenyl-, ethyl ester,
 (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



AB The total synthesis of thiagazole, a tris-thiazoline-oxazole metabolite isolated from Polyangium spec. strain PI 3007, is described utilizing the stepwise formation of the thiazoline moieties with Et (R)-2-methyl-cysteine which is obtained by preparative HPLC-separation of the racemic 2-phenylthiazoline derivative I followed by acidic hydrolysis.

IT 158785-69-4P 158785-72-9P 158850-80-7P
 158850-81-8P
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (total synthesis of thiagazole)


RN 158785-69-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-phenyl-, ethyl ester
 (9CI) (CA INDEX NAME)



RN 158785-72-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[(diphenylphosphinyl)methyl]-4,5-dihydro-4-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:631130 CAPLUS
 DOCUMENT NUMBER: 121:231130
 TITLE: Total synthesis of didehydromirabazole A and revision of stereostructure
 AUTHOR(S): Boyce, Richard J.; Pattenden, Gerald
 CORPORATE SOURCE: Dep. Chem., Univ. Nottingham, Nottingham, NG7 2RD, UK
 SOURCE: Synlett (1994), (8), 587-8
 CODEN: SYNLES; ISSN: 0936-5214
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB A new total synthesis of didehydromirabazole A, shows that its stereostructure should be revised to I.
 IT 158252-58-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (total synthesis of didehydromirabazole A and revision of stereostructure)
 RN 158252-58-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-(1-methylethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L4 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:605775 CAPLUS
 DOCUMENT NUMBER: 121:205775
 TITLE: Total synthesis of thiagazole, a novel inhibitor of HIV-1 from Polyangium sp
 AUTHOR(S): Boyce, Richard J.; Mulqueen, Gerard C.; Pattenden, Gerald
 CORPORATE SOURCE: Department of Chemistry, The University, Nottingham, NG7 2RD, UK
 SOURCE: Tetrahedron Letters (1994), 35(31), 5705-8
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 121:205775
 GI




AB A concise total synthesis of the cinnamyl-oxazole substituted tris-thiazoline containing metabolite thiagazole (I) was achieved via coupling of II and III.
 IT 157770-61-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in total synthesis of thiagazole)
 RN 157770-61-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-(2-phenylethenyl)-, methyl ester, [R-(E)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.



L4 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:408937 CAPLUS
 DOCUMENT NUMBER: 121:8937
 TITLE: Thiazohalostatin, a new cytoprotective substance produced by Actinomadura. II. Physico-chemical properties and structure determination
 AUTHOR(S): Shindo, Kazutoshi; Yamagishi, Yuji; Kawai, Hiroyuki
 CORPORATE SOURCE: Pharm. Res. Lab., Kirin Brew. Co., Ltd., Takasaki, 370-12, Japan
 SOURCE: Journal of Antibiotics (1993), 46(11), 1638-42
 CODEN: JANTAJ; ISSN: 0021-8820
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB The structure of thiazohalostatin (I) was elucidated by NMR spectral analyses and chemical modifications. Fermentation of Actinomadura sp. HQ24 in the presence of KBr gave the tribromo analog of I.
 IT 154914-54-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, from thiazohalostatin)
 RN 154914-54-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-[(1,3,5,7-tetramethyl-6,8-dioxo-8-(3,4,5-trichloro-1-methyl-1H-pyrrol-2-yl)octyl)]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:164618 CAPLUS
 DOCUMENT NUMBER: 120:164618
 TITLE: Naturally occurring linear fused thiazoline-thiazole containing metabolites: total synthesis of (-)-didehydromirabazole A, a cytotoxic alkaloid from blue-green algae
 AUTHOR(S): Pattenden, Gerald; Thom, Stephen M.
 CORPORATE SOURCE: Dep. Chem., Univ. Nottingham, NG7 2RD, UK
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1993), (14), 1629-36
 CODEN: JCPRB4; ISSN: 0300-922X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 120:164618
 GI


L4 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A concise total synthesis of the thiazoline-thiazole containing metabolite didehydromirabazole A (I) is described. The synthesis uses the unusual amino acid (R)-2-methylcysteine in sequential cyclocondensations with imino ethers as key steps, viz Me2C(=NH)OMe → II and III → IV.
 IT 143207-48-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and amidation of)
 RN 143207-48-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-(1-methylethyl)-, methyl ester, (R)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.




IT 153060-83-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 153060-83-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-(1-methylethyl)-, methyl ester (SCI) (CA INDEX NAME)

L4 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:571790 CAPLUS
 DOCUMENT NUMBER: 117:171790
 TITLE: Cytotoxic alkaloids from blue-green algae: a total synthesis of (-)-didehydromirabazole A
 AUTHOR(S): Pattenden, Gerald; Thom, Stephen M.
 CORPORATE SOURCE: Dep. Chem., Univ. Nottingham, Nottingham, NG7 2RD, UK
 SOURCE: Synlett (1992), (6), 533-7
 CODEN: SYNLES; ISSN: 0936-5214
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 117:171790
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A concise total synthesis of the thiazole-thiazoline based metabolite from (-)-didehydromirabazole A (I), a cytotoxic alkaloid isolated recently from the blue-green alga Scytonema mirabile, is described which uses sequential cyclocondensation reactions with Me (R)-2-methylcysteine hydrochloride as key steps via thiazoles II and III.
 IT 143207-48-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and amidation of)
 RN 143207-48-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-methyl-2-(1-methylethyl)-, methyl ester, (R)- (SCI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:41586 CAPLUS
 DOCUMENT NUMBER: 116:41586
 TITLE: Addition of trimethylsulfoxonium ylide and methylenetriphenylphosphorane to N2-(thioacyl)amidines
 AUTHOR(S): Toure, S. A.; Voglozin, A.; Degny, E.; Danion-Bougout, R.; Danion, D.; Pradere, J. P.; Toupet, L.; N'Guessan, Y. T.
 CORPORATE SOURCE: Lab. Chim. Org. Struct., Fac. Sci. Tech., Abidjan, Cote d'Ivoire
 SOURCE: Bulletin de la Societe Chimique de France (1991), (July-Aug.), 574-9
 CODEN: BSCFAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 OTHER SOURCE(S): CASREACT 116:41586
 GI




AB Trimethylsulfoxonium ylide reacts with 4-dimethylamino-1-thia-3-azabutadienes RC(S)N:CR1NMe2 (R = Ph, R1 = H, CO2Et; R = PhCH2S, R1 = Me, CO2Et) (N2-thioacylamidines) affording thiazol-2-ines I through a regioselective reaction corresponding to a nucleophilic attack on the amidine group. Thiazoles are obtained by reaction of Ph isocyanate with 4-aminothiazol-2-ines. Addition of methylenetriphenylphosphorane to N2-acyl or N2-thioacylamidines occurs by a similar pathway, but the intermediate betaine is stable at room temperature. Hydrolysis affords a dimethylaminovinylphosphonium salt Me2NCH=CHP(Ph)3 Br-. In boiling toluene or THF, dimethylamine elimination occurs, leading to N-acyl or N-thioacyliminoethylidenetriphenylphosphoranes. An x-ray structural determination of the latter, PhC(O)N:CHCH:PPH3, is achieved.
 IT 127956-59-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 127956-59-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4-(dimethylamino)-4,5-dihydro-2-phenyl-, ethyl ester (SCI) (CA INDEX NAME)




L4 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1988:473375 CAPLUS
 DOCUMENT NUMBER: 109:73375
 TITLE: The synthesis of 1-[(2-thiazolyl)methyl]quinolones. The reactivity of the methylene bridge at position-1 and its involvement in the formation of a stable carbon-nitrogen ylide
 AUTHOR(S): Izzo, Patrick T.; Lee, Ving J.
 CORPORATE SOURCE: Med. Res. Div., Am. Cyanamid Co., Pearl River, NY, 10965, USA
 SOURCE: Journal of Heterocyclic Chemistry (1988), 25(1), 289-95
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 109:73375
 GI




AB Thiazolylmethylquinolinecarboxylates I (R1 = R2 = Me, R1 = Me, CO2Et, R2 = H) were prepared from Et 7-chloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylate in 4 steps. Dehydration of the intermediate 4-hydroxythiazolines II with (CF3CO)2O resulted in the formation of ylides. Evidence for the formation of the ylide was obtained by the
 x-ray anal. of the analogous ylide III, obtained in the reactions carried out with 4-pyridone.
 IT 115698-10-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


L4 ANSWER 34 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1990:440532 CAPLUS
 DOCUMENT NUMBER: 113:40532
 TITLE: N-Thioacylformamides: 1,3-dipolar cycloadditions. Synthesis of substituted thiazolines
 AUTHOR(S): Danion-Bougot, Renee; Tuloup, Remy; Danion, Daniel; Pradere, Jean Paul; Tonnard, Francois
 CORPORATE SOURCE: Groupe Rech. Physicochim. Struct., Univ. Rennes 1, Rennes, F-35042, Fr.
 SOURCE: Sulfur Letters (1989), 9(6), 245-51
 CODEN: SULED2; ISSN: 0278-6117
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 OTHER SOURCE(S): CASREACT 113:40532
 GI




AB CH2N2 reacted with N-thioacylformamides and formamides to give thiazolines. E.g., reaction of PhC(S)N:CHNMe2 with CH2N2 gave 54% and 32% of the thiazolines I and II, resp., as well as triazole III. The reactions involved cycloaddn. to the thiocarbonyl functions.
 IT 127956-59-6P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 127956-59-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4-(dimethylamino)-4,5-dihydro-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. and reaction of, with trifluoroacetic anhydride)
 RN 115698-10-7 CAPLUS
 CN 3-Quinolinecarboxylic acid, 7-chloro-1-[(4-(ethoxycarbonyl)-4,5-dihydro-4-hydroxy-2-thiazolyl)methyl]-6-fluoro-1,4-dihydro-4-oxo-, ethyl ester (9CI)
 (CA INDEX NAME)




L4 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1988:22219 CAPLUS
 DOCUMENT NUMBER: 108:22219
 TITLE: Amino acids and peptides: 58. Synthesis of optically active 2-(1-hydroxyalkyl)thiazole-4-carboxylic acids and 2-(1-aminoalkyl)thiazole-4-carboxylic acids
 AUTHOR(S): Schmidt, U.; Gleich, P.; Griesser, H.; Utz, R.
 CORPORATE SOURCE: Isotopenforsch., Univ. Stuttgart, Stuttgart, D-7000/80, Fed. Rep. Ger.
 SOURCE: Synthesis (1986), (12), 992-8
 CODEN: SYNTBF; ISSN: 0039-7881
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 108:22219
 GI



AB Title hydroxyalkyl compds. I (R = Me, CH₂CHMe₂, CH₂Me, CHMe₂, CH₂Ph) were prepared from the corresponding (S)-AcOCHRCNH₂ (II). Thus, II were converted into thioamides (S)-AcOCHRCNSNH₂, which were cyclized with BrCH₂CO₂CO₂Et to give thiazolines III, which were dehydrated with (CF₃CO)₂O to give I. Title (R)-amino acids IV (Boc = Me₃CO₂C; R = Me, R₁ = Et; R = CH₂CHMe₂, R₁ = Me) were prepared from the corresponding I in several steps.
 Title (S)-amino acids V (R = Me, CH₂Me, R₂ = PhCH₂CO₂C; R = CH₂CHMe₂, R₂ = Boc) were prepared from (S)-R₃NHCHRCNSNH₂ in 2 steps.
 IT 111946-81-7P 111946-82-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and dehydration of)
 RN 111946-81-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[1-(acetyloxy)ethyl]-4,5-dihydro-4-hydroxy-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 111946-82-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[1-(acetyloxy)ethyl]-4,5-dihydro-4-hydroxy-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L4 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1977:121230 CAPLUS
 DOCUMENT NUMBER: 86:121230
 TITLE: Cyclic peroxides. 42. Direct α -lithiation of 4,5-dihydro-1,3-thiazole-4-carboxylic acids and electrophilic substitution
 AUTHOR(S): Adam, Waldemar; Ehrig, Volker
 CORPORATE SOURCE: Dep. Chem., Univ. Puerto Rico, Rio Piedras, P. R.
 SOURCE: Synthesis (1976), (12), 817-19
 CODEN: SYNTBF; ISSN: 0039-7881
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Thiazoles I (R = D, OH, Me, CH₂Ph, CHMe₂OH, 1-hydroxycyclohexyl, CHPhOH, R₁ = CO₂H, R₂ = H; R = D, R₁ = CO₂H, R₂ = Me; R = D, OH, CO₂Et, R₁ = CO₂Me, R₂ = H; RR₁ = C(OSiMe₃)₂, R₂ = H; RR₁ = O, R₂ = Me) were obtained in 48-95% yield by treating I (R = H, R₁ = CO₂H, CO₂Me, R₂ = H, Me) with 2 equiv BuLi and electrophiles.
 IT 62175-47-7P 62175-48-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 62175-47-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-hydroxy-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 62175-48-8 CAPLUS
 CN 4,4(SH)-Thiazolecarboxylic acid, 2-phenyl-, ethyl methyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 38 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1976:462973 CAPLUS
 DOCUMENT NUMBER: 85:62973
 TITLE: Reactivity of peptide hydroxamates. A model for the biosynthesis of β -lactam antibiotics
 AUTHOR(S): Scott, A. Ian; Yoo, Sung Eun; Chung, Sung-Kee; Lacadie, John A.
 CORPORATE SOURCE: Chem. Dep., Yale Univ., New Haven, CT, USA
 SOURCE: Tetrahedron Letters (1976), (15), 1137-40
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB The sulfone I (X = SO₂, R = SO₂C₆H₄NO₂-4), prepared from the hydroxamic acid I (X = S; R = H) by treatment with 4-O₂NC₆H₄SO₂Cl and Et₃N followed by per acid oxidation, with 1.1 equiv KO₂Me₃ in THF overnight at -78° to room temperature gave approx. 50% β -lactam II. The cyclization mimics the stereochem. fate of cysteine β -protons in the biosynthesis of β -lactam antibiotics.
 IT 50297-49-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 50297-49-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-(4-methoxyphenyl)-4-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 39 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1975:564060 CAPLUS
 DOCUMENT NUMBER: 83:164060
 TITLE: Biogenetic-type synthesis of penicillin-cephalosporin antibiotics. II. Oxidative cyclization route to β -lactam thiazoline derivatives
 AUTHOR(S): Nakatsuka, Shinichi; Tanino, Hideo; Kishi, Yoshito
 CORPORATE SOURCE: Dep. Chem., Harvard Univ., Cambridge, MA, USA
 SOURCE: Journal of the American Chemical Society (1975), 97(17), 5010-12
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB An oxidative cyclization method to construct the β -lactam thiazoline ring system is reported. Using the oxidative cyclization reaction as a key step, the β -lactam thiazoline dehydrovaline I was synthesized by two different sequences of the reactions, which would present a solution of the biogenetic-type synthesis of the penicillin-cephalosporin antibiotics.
 To extend the present method for synthesis of 6H-penamams and 7H-cephems, a method to oxidize II to III was developed.
 IT 57001-62-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and conversion into amide)
 RN 57001-62-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-2-(4-methoxyphenyl)-4-methyl-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 40 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1973:492203 CAPLUS
 DOCUMENT NUMBER: 79:92203
 TITLE: Thiazolines
 INVENTOR(S): Arakawa, Kiichi
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48048466	A2	19730709	JP 1971-82629	19711018
JP 55016145	B4	19800430		

PRIORITY APPLN. INFO.: JP 1971-82629 A 19711018

GI For diagram(s), see printed CA Issue.
 AB The title compds. (I), were prepared from amines R₁C₂NH₂ (R₁ = alkyl or aryl) and halides R₂COCH₂NR₃ (R₂ = alkyl, alkoxy, carbonyl, or their deriva.: R₃ = halogen). I were bactericides and plant growth regulators. E.g., 1.93 g Et bromopyruvate in Me₂CO was treated with 800 mg thioacetamide to give 79% I.HBr: (R₁ = Me, R₂ = CO₂Et). Among 6 more I similarly prepared were I (R₁ and R₂ given): Ph, CO₂Et; Me, Cl; NOH; Me; Me, CH₂Cl; Ph, CH₂Cl; Me, Me.
 IT 37128-20-4P 50639-62-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 37128-20-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-hydroxy-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 50639-62-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-hydroxy-2-methyl-, ethyl ester, hydrobromide (9CI) (CA INDEX NAME)



• HBr

L4 ANSWER 40 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 41 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1972:501446 CAPLUS
 DOCUMENT NUMBER: 77:101446
 TITLE: Synthesis of N-free 4-hydroxy-2-thiazoline as an intermediate in the Hantzsch thiazole synthesis
 AUTHOR(S): Arakawa, Kiichi; Miyasaka, Tadashi; Ohtsuka, Hiroko
 CORPORATE SOURCE: Sch. Pharm. Sci., Showa Univ., Tokyo, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1972), 20(5), 1041-6
 CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB 4-Hydroxy-2-thiazolines (I, R = Me, Ph, R1 = CH2CO2Et, Me, ClCH2, Ph, etc.) were prepared by interrupting the Hantzsch thiazole synthesis at the stage of cyclization. The chemical behavior of the tertiary amines, as well as the AB-quartet pattern at around 3.5 ppm in the NMR spectra, supported the cyclic structure I. The thioliminoester structure proposed by M. Steude (1891) was unambiguously denied by the present paper.
 IT 37128-15-7P 37128-20-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 37128-15-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-hydroxy-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 37128-20-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 4,5-dihydro-4-hydroxy-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

